The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype

Blood

Volumn 97, Issue 1, 2001, Pages 277-287

  Zhang, Xiaowu ^b   Wong, Ray ^b   Hao, Sheryl X ^b   Pear, Warren S ^b   Ren, Ruibao ^a  

^a BRANDEIS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PHOSPHOTRANSFERASE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL SELECTION; CHRONIC MYELOID LEUKEMIA; DISEASE ACTIVITY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; LYMPHOCYTE; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RETROVIRUS; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING;

EID: 0035174344     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.1.277     Document Type: Article

References (66)

1. Chronic myeloid leukemia
2. BCR-ABL gene variants
3. Chronic myeloid leukemia
4. Reversibility of acute B-cell leukemia induced by BCR-ABL1
5. The biology of chronic myeloid leukemia
6. Abl tyrosine kinase in signal transduction and cell-cycle regulation
7. Signal transduction by wild-type and leukemogenic Abl proteins
8. Growth factor independence and BCR/ABL transformation: Promise and pitfalls of murine model systems and assays
9. Modular binding domains in signal transduction proteins
10. Protein modules and signaling networks
11. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner
12. A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction
13. Crystal structures or the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition
14. Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates Pl 3-kinase association with tyrosine-phosphorylated proteins
15. Src homology 2 domain as a speciticity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain
16. Evidence that SH2 domains promote processive pholphorylation by protein-tyrosine kinases
17. Getting down to specifics
18. Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok
19. p62(dok): A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells
20. Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins
21. Interactipns of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells
22. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1
23. Tyrosine phosphorylation of tab and its association with Src homology 2 domain-containing proteins implicate tub in intracellular signaling by insulin
24. Mouse disabled (mDab1): A Src binding protein implicated in neuronal development
25. In vivo association of v-Abl with Shc mediated by a non-phosphotyrosine-dependent SH2 interaction
26. Differential complementation of Bcr-Abl point mutants with c-Myc
27. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias
28. Alternative signals to RAS for hemalopoietic transformation by the Bcr-Abl oncogene
29. Structural and signaling requirments for Bcr-Abl-mediated transformation and inhibition of apoptosis
30. The SH2 domain of Abl is not required for factor independent growth induced by Bcr-Abl in a murine myeloid cell line
31. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells
32. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
33. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
34. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice
35. Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions
36. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL [published erratum appears in Proc Natl Acad Sci U S A 1990;87:9072]
37. Efficient transplantation of Bcr-Abl-induced chronic myelogenous leukemia-like syndrome in mice
38. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia
39. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow
40. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
41. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy
42. Production of high-titer helper-free retroviruses by transient transfection
43. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites
44. Proline-rich sequences that bind to Src homology 3 domains with individual specificities
45. Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein, Sin
46. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo
47. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
48. Acute leukemia in bcr/abl transgenic mice
49. Expression of p210bcr-abl by metallothionein promoter induced T-cell leukemia in transgenic mice
50. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: A novel transgenic model for human Ph1-positive leukemias
51. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice
52. bcr-abl oncogene renders myeloid cell line factor independent: Potential autocrine mechanism in chronic myeloid leukemia
53. Expression of bacr-abl abrogates factor-dependent growth of human hematopoietic MO7E cells by an autocrine mechanism
54. The Bcr-Abl oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion
55. Granulocyte macrophage colony stimulating factor and interleukin-6 enhanced white blood cell synthesis of leukotrienes in chronic myelogenous leukemia
56. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors
57. Constitutive expression of GM-CSF mRNA by CML blast cells is correlated with endogenous megakaryocytic colony formation
58. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia
59. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells
60. Anti-apoptotic activity of stat5 required during terminal stages of myeloid differentiation
61. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/-mice: A direct role for Stat5 in Bcl-X(L)induction
62. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells
63. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis
64. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells
65. BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells
66. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581